Insider buying last 90 days
No open-market insider purchases were filed for LLY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LLY insider filing, plotted on the chart in Gekko.Open LLY in Gekko
NYSE: LLY
Eli Lilly (LLY) Stock Analysis & Forecast
Nov 4 close
$1,417.99+8.61 (+0.6%)
Gekko Brief
AI summaryNov 4 closeEli Lilly's week is dominated by its Q3 results, posted 29 October, which showed revenue growth of 39% year over year, approaching $7 billion in incremental revenue versus Q3 2025, with gross margin at 84.4% and non-GAAP EPS of $7.48 against an estimate of $5.71. Coverage notes that growth was driven by 53% volume gains offsetting a 15% decline in realized prices, with gross margin cited elsewhere at 83.9%, and that acquired R&D charges of $4.57 per share weighed on earnings. The stock has risen 9.6% since the report, and commentary has ranged from AI-driven drug discovery potential to speculation about Lilly surpassing Nvidia in market value, alongside continued attention to Mounjaro and Zepbound demand.
The stock closed at $1,417.99, up 0.6%, sitting above both its 50-day average of $1,207.17 and 200-day average of $1,096.87, with the shorter average above the longer one, consistent with an established uptrend. The GekkoIndex reading of 39.4 places it in the Distribution zone, while price stands 27.7% above the Gekko Fair Value of $1,110.68.
The next earnings date falls on 3 February 2027, outside a typical 20-trading-day holding window. Over the last 90 days, Congress recorded 1 buy and 0 sales. Seasonality over five years shows the next 20 trading days averaging a 2.4% return, higher in 4 of those years. Analyst consensus among 24 firms stands at 22 buy, 1 hold, 1 sell, with a consensus target of $1,426.92.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Eli Lilly price vs fair value
Close $1,417.99200-day averageGekko Fair Value $1,110.68
Eli Lilly quick facts
- Market cap
- $1.33T
- P/E ratio
- 46
- Forward P/E
- 29.7
- EPS, TTM
- $30.67
- Revenue, TTM
- $86.46B
- Profit margin
- 31.9%
- Dividend yield
- 0.47%
- Beta
- 0.39
- Volume
- 3.63M avg 2.70M
- 1-year return
- +58.2%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±5.9%
- 50-day average
- $1,207.17
- 200-day average
- $1,096.87
- Next earnings
- Feb 3
- Shares outstanding
- 890.7M
Eli Lilly swing-trade checklist
Eli Lilly scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $1417.99 is above the 50-day ($1207.17) and 200-day ($1096.87) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
39.4, Distribution
Reading 39.4 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
27.7% above
Price is 27.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 90 days
Next report Feb 3, 2027, 90 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.4% on average
From this point in the calendar, the next 20 trading days averaged +2.4% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Eli Lilly stock chart and price history
Eli Lilly closed at $1,417.99 on Nov 4, 2026, +58.2% over the past year, inside a 52-week range of $850.51 to $1,449.68.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +22.5%
- 3 months
- +19.0%
- 6 months
- +43.7%
- 1 year
- +58.2%
The full LLY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LLY in Gekko
Follow Eli Lilly through every session
Put LLY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LLY in GekkoFree for 7 days. No credit card required.
About Eli Lilly
Eli Lilly develops and sells medicines for patients worldwide, with a name most associated with its long-running diabetes care line. Its treatments span insulin products such as Basaglar, Humalog, and Humulin, alongside type 2 diabetes therapies including Jardiance, Trajenta, and Trulicity, making this area a central part of its business.
Beyond diabetes, the company markets medicines across several other areas of health. In oncology it offers treatments like Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio for various cancers, while Olumiant and Taltz address autoimmune and inflammatory conditions. It also supplies medicines for neurological and pain-related conditions, including Cymbalta, Emgality, and Zyprexa, along with Cialis, Forteo, and antibody treatments developed for COVID-19. The company works with a range of partners, among them Incyte, Boehringer Ingelheim, AbCellera, Junshi Biosciences, and Regor Therapeutics, to support its research and development efforts.
Eli Lilly's shares are listed on the NYSE under the ticker LLY.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- lilly.com
Eli Lilly GekkoIndex: the smart money zone
Eli Lilly’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 39.4, in the Distribution zone, down 9.5 points over five sessions.
39.4Distribution
Down 9.5 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 32 | +3.1% | +7.1% |
| Accumulation | 203 | +0.9% | +3.8% |
| Neutral | 383 | +0.2% | +1.2% |
| Distribution (current zone) | 68 | +1.2% | +1.5% |
| Selling | 11 | +2.4% | +4.6% |
Average LLY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the LLY price, zone by zone.Track LLY in Gekko
Is Eli Lilly stock overvalued? Gekko Fair Value
Eli Lilly trades 27.7% above Gekko Fair Value of $1,110.68, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Eli Lilly shares are worth, recalculated every trading day.
$1,110.68
Gekko Fair Value, Nov 4, 2026
27.7% Overvalued
At the end of Aug 2026 the price was 22.8% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open LLY in Gekko
Eli Lilly insider and Congress trading
No open-market insider purchases were filed for Eli Lilly, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Eli Lilly has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2026
- $377.0M
- As a share of market cap
- 0.03%
- Trailing four quarters
- $5.84B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
4of the funds Gekko tracks hold LLY.
1added3opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Eli Lilly earnings: next date and track record
Eli Lilly reports on Feb 3, 2027 (90 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 3, 2027
90 days away
- EPS estimate
- $11.16
- Revenue estimate
- $24.51B
8 of 8reports beat the EPS estimate
±8.3%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- LLY posted Q3 revenue growth of 39% YoY, approaching $7B incremental revenue vs Q3 2025, with gross margin at 84.4%. Key products in oncology, immunology, and neuroscience doubled revenue. Non-GAAP EPS was $7.48 vs $7.20 prior year. The Medicare GLP-1 bridge program saw 500K+ prescriptions filled, with Lilly capturing 70% of new patients. Two major manufacturing facilities broke ground totaling $11.5B investment.
- Guidance
- Management raised full-year financial guidance following strong Q3 execution. Revenue growth trajectory supported by Mounjaro, Zepbound volume expansion, and global Foundayo rollout across new markets including UK, Mexico, and Saudi Arabia.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $7.48 est $5.71 | $24.40B est $22.58B | +10.0% |
| Aug 5, 2026 | $8.38 est $6.01 | $22.97B est $20.69B | +6.8% |
| Apr 30, 2026 | $8.55 est $7.25 | $19.80B est $17.82B | +13.2% |
| Feb 4, 2026 | $7.54 est $6.91 | $19.29B est $17.94B | +1.7% |
| Oct 30, 2025 | $7.02 est $5.69 | $17.60B est $16.05B | +6.1% |
| Aug 7, 2025 | $6.31 est $5.60 | $15.56B est $14.70B | −16.2% |
| May 1, 2025 | $3.34 est $3.26 | $12.73B est $12.67B | −8.4% |
| Feb 6, 2025 | $5.32 est $5.03 | $13.53B | +4.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Eli Lilly stock forecast and analyst price targets
Analysts’ average 12-month price target for Eli Lilly is $1,426.92, +0.6% from the last close, from 24 firms rating the stock in the last 90 days.
$1,426.92consensus 12-month target, +0.6% from the last close
Now $1,417.99Avg $1,426.92
Low $940High $1,650
Each firm’s latest rating in the last 90 days: 24 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Cantor Fitzgerald | $1,600 | +12.8% |
| Nov 2 | BMO Capital | $1,650 | +16.4% |
| Nov 2 | Leerink Partners | $1,508 | +6.3% |
| Oct 30 | Citi | $1,650 | +16.4% |
| Oct 30 | UBS | $1,625 | +14.6% |
+1.5%average 20-day move after past Distribution readings
+2.4%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Eli Lilly seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Eli Lilly averaged +2.4% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.6% | 3 of 5 |
| Next 10 trading days | +1.1% | 3 of 5 |
| Next 15 trading days | +3.7% | 3 of 5 |
| Next 20 trading days | +2.4% | 4 of 5 |
| Next 30 trading days | +2.5% | 3 of 5 |
For scale, LLY’s typical 20-trading-day move in either direction is about 5.9%.
Eli Lilly market cap and key statistics
Eli Lilly’s market cap is $1.33T, with a P/E ratio of 46 and revenue of $86.46B over the last twelve months.
Valuation
- Market cap
- $1.33T
- P/E ratio
- 46
- Forward P/E
- 29.7
- EPS, TTM
- $30.67
- Gekko Fair Value
- $1,110.68
Trading
- Volume
- 3.63M
- Avg volume, 20 days
- 2.70M
- 52-week high
- $1,449.68
- 52-week low
- $850.51
- Shares outstanding
- 890.7M
Financials
- Revenue, TTM
- $86.46B
- Profit margin
- 31.9%
- Return on equity
- 86%
- Quarterly earnings growth, YoY
- +16.3%
Risk and income
- Beta
- 0.39
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±5.9%
- Dividend yield
- 0.47%
Eli Lilly stock news this week
Coverage of Eli Lilly this week reads positive: 7 positive, 0 neutral and 0 negative headlines.
- Eli Lilly, Regeneron Lead Weight-Loss ETF THNR HigherETF Database, Nov 4
- Eli Lilly: The True Frontier Of Real-World AI MonetizationSeeking Alpha, Nov 4
- Eli Lilly: Higher Volume, Lower Realized PricesSeeking Alpha, Nov 4
- Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro InvestorTIKR.com, Nov 3
- Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research, Nov 3
- LLY Stock Up Almost 10% After a Robust Q3: Time to Buy, Sell or Hold?Zacks Investment Research, Nov 3
Eli Lilly peers
Eli Lilly’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
| VRTXVertex Pharmaceuticals | Neutral | 16.8% above |
A peer links to its own page where one exists.
Eli Lilly stock FAQ
What is Eli Lilly’s market cap?
Eli Lilly’s market cap is $1.33T at the Nov 4, 2026 close of $1,417.99, with 890.7M shares outstanding. The shares trade on a P/E ratio of 46.
What is the Eli Lilly stock forecast?
The consensus analyst 12-month price target for Eli Lilly is $1,426.92, +0.6% from the last close. Of the 24 firms that rated the stock in the last 90 days, 22 rate it a buy, 1 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Eli Lilly stock overvalued or undervalued?
On Gekko’s estimate Eli Lilly is overvalued: the Nov 4, 2026 close of $1,417.99 is 27.7% above Gekko Fair Value of $1,110.68. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Eli Lilly report earnings next?
Eli Lilly is expected to report on Feb 3, 2027 (90 days away). Analysts expect earnings of $11.16 per share on revenue of $24.51B. Eli Lilly beat the earnings estimate in 8 of its last 8 reports, moving 8.3% on average across the report.
What is Eli Lilly’s 52-week high and low?
Eli Lilly’s 52-week high is $1,449.68 and its 52-week low is $850.51; it closed at $1,417.99 on Nov 4, 2026, +58.2% over the past year.
Is Eli Lilly stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Eli Lilly the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.